Clesrovimab: New RSV Prevention for Infants
Content reviewed against published CDC, AAP, NIH guidelines
Last reviewed:
If your baby has been diagnosed with or you suspect clesrovimab: new rsv prevention for infants, here is what the evidence says.
The short answer
Clesrovimab is a long-acting monoclonal antibody being developed for the prevention of RSV (respiratory syncytial virus) lower respiratory tract disease in infants. Similar to nirsevimab (Beyfortus), it provides passive immunity against RSV by giving babies ready-made antibodies. This approach is especially important because RSV remains a leading cause of infant hospitalization, and infants under 6 months are too young for active vaccination. Consult your pediatrician about the latest RSV prevention options for your baby.
Key takeaways
- Clesrovimab is a long-acting monoclonal antibody being developed for the prevention of RSV (respiratory syncytial virus) lower respiratory tract disease in infants. Similar to nirsevimab (Beyfortus), it provides passive immunity against RSV by giving babies ready-made antibodies. This approach is especially important because RSV remains a leading cause of infant hospitalization, and infants under 6 months are too young for active vaccination. Consult your pediatrician about the latest RSV prevention options for your baby.
- Usually normal when: Your baby received RSV prophylaxis (nirsevimab or clesrovimab) and has no adverse effects beyond mild injection site reactions.
- Call your doctor if: Your baby shows signs of RSV infection (wheezing, fast breathing, nasal flaring, poor feeding) regardless of whether they received prophylaxis.
- Varies by age — see the age-by-age breakdown below
“Fever itself is not an illness — rather, it is a sign or symptom that the body is fighting an infection. Fever stimulates certain defenses, such as the white blood cells, which attack and destroy invading bacteria.”
Thousands of parents search for this exact thing. You are not alone.
When to Seek Immediate Care
- Your baby shows signs of RSV infection (wheezing, fast breathing, nasal flaring, poor feeding) regardless of whether they received prophylaxis.
- Your baby develops a severe allergic reaction after receiving any RSV prophylaxis (difficulty breathing, facial swelling, widespread hives).
- Your infant under 3 months develops any respiratory illness with breathing difficulty during RSV season.
By Age
What to expect by age
0-3 months
Newborns and young infants are at highest risk for severe RSV disease. RSV monoclonal antibodies like clesrovimab are designed to be given as a single injection, typically before or during the RSV season, to provide protection for approximately 5 months. For babies born during RSV season (typically October through March in the Northern Hemisphere), the injection would ideally be given shortly after birth. This is particularly important for this age group, as they cannot receive active RSV vaccines.
3-6 months
Babies in this age range remain at significant risk for severe RSV. If your baby did not receive RSV immunoprophylaxis at birth, they may still be eligible for a dose before or during RSV season. The protection from monoclonal antibodies like clesrovimab provides coverage during the highest-risk period. Talk to your pediatrician about whether your baby should receive RSV prophylaxis, especially if they are entering their first RSV season.
6-24 months
While RSV risk decreases somewhat with age, children in their first two years are still vulnerable, especially those born prematurely, with chronic lung disease, or with congenital heart disease. RSV immunoprophylaxis recommendations may extend to older high-risk infants. As new products become available, the recommendations may evolve. Your pediatrician can advise whether RSV prophylaxis is recommended for your child based on their risk factors and the current season.
What Should You Do?
When to take action
- Your baby received RSV prophylaxis (nirsevimab or clesrovimab) and has no adverse effects beyond mild injection site reactions.
- Your baby goes through RSV season without developing significant respiratory illness after receiving prophylaxis.
- Your pediatrician discusses RSV prevention options and recommends the best available option for your baby.
- You are unsure whether your baby has received RSV prophylaxis and RSV season is approaching.
- Your baby has risk factors for severe RSV (prematurity, chronic lung disease, congenital heart disease) and you want to discuss prevention options.
- You have questions about the difference between available RSV prevention products.
- Your baby shows signs of RSV infection (wheezing, fast breathing, nasal flaring, poor feeding) regardless of whether they received prophylaxis.
- Your baby develops a severe allergic reaction after receiving any RSV prophylaxis (difficulty breathing, facial swelling, widespread hives).
- Your infant under 3 months develops any respiratory illness with breathing difficulty during RSV season.
Doctor Visit Checklist
Bring this checklist to your next pediatrician visit to discuss Clesrovimab: New RSV Prevention for Infants.
Things to mention
- You are unsure whether your baby has received RSV prophylaxis and RSV season is approaching.
- Your baby has risk factors for severe RSV (prematurity, chronic lung disease, congenital heart disease) and you want to discuss prevention options.
- You have questions about the difference between available RSV prevention products.
Observations to share
- You are unsure whether your baby has received RSV prophylaxis and RSV season is approaching.
- Your baby has risk factors for severe RSV (prematurity, chronic lung disease, congenital heart disease) and you want to discuss prevention options.
- You have questions about the difference between available RSV prevention products.
Urgent signs to report immediately
- Your baby shows signs of RSV infection (wheezing, fast breathing, nasal flaring, poor feeding) regardless of whether they received prophylaxis.
- Your baby develops a severe allergic reaction after receiving any RSV prophylaxis (difficulty breathing, facial swelling, widespread hives).
- Your infant under 3 months develops any respiratory illness with breathing difficulty during RSV season.
My notes
From ismybabyalright.com — free, evidence-based baby health guides
Related Conditions
RSV in Babies: What to Know
RSV (respiratory syncytial virus) is a common virus that affects nearly all children by age 2. Most babies have mild cold-like symptoms, but some, especially young infants and those with underlying conditions, can develop breathing difficulties. Watch for fast breathing, flaring nostrils, or visible chest pulling - these are signs to seek medical care.
Signs of Bronchiolitis in Babies
Bronchiolitis is a common lower respiratory infection in babies under 2 years, most often caused by RSV. It typically starts like a cold with runny nose and cough, then progresses to wheezing and breathing difficulty over 2-3 days. Most cases are mild and resolve at home within 1-2 weeks, but young infants (under 3 months) and babies born prematurely are at higher risk for severe illness requiring hospitalization.
Childhood Immunization Schedule: 2026 Updates
The childhood immunization schedule is reviewed and updated annually by the CDC's Advisory Committee on Immunization Practices (ACIP), the AAP, and the American Academy of Family Physicians. The schedule may include changes to timing, new vaccine recommendations, or updates to catch-up schedules. Always consult your pediatrician for the most current recommendations, as the schedule is designed to provide the earliest possible protection during the most vulnerable periods.
Related Resources
Vaccine Schedule Tracker
Track vaccinations, see what's due, and understand each vaccine.
Month-by-Month Development
Detailed monthly development guides from birth through 24 months.
When to Call the Doctor
General guide on when to call the pediatrician, visit urgent care, or go to the ER.
Frequently asked questions
Is clesrovimab: new rsv prevention for infants normal?
When should I call the doctor about clesrovimab: new rsv prevention for infants?
When is clesrovimab: new rsv prevention for infants normal?
What causes clesrovimab: new rsv prevention for infants?
What should I mention to my pediatrician about clesrovimab: new rsv prevention for infants?
Is clesrovimab: new rsv prevention for infants normal at 0-3 months?
Is clesrovimab: new rsv prevention for infants normal at 3-6 months?
Should I go to the ER for clesrovimab: new rsv prevention for infants?
Does clesrovimab: new rsv prevention for infants go away on its own?
References
- [1]Centers for Disease Control and Prevention. RSV Immunization for Infants and Young Children. CDC, 2024. CDC
- [2]American Academy of Pediatrics. Updated Guidance for Palivizumab Prophylaxis and RSV Immunoprophylaxis. Pediatrics. AAP
- [3]National Institutes of Health. Monoclonal Antibodies for RSV Prevention in Infants. ClinicalTrials.gov. NIH
All content follows our editorial policy and is reviewed against published clinical guidelines.
2,705 evidence-based guides6 authoritative medical sources
Related Resources
Bottom line
Most cases of clesrovimab: new rsv prevention for infants are normal. Talk to your pediatrician if your baby shows signs of rsv infection (wheezing, fast breathing, nasal flaring, poor feeding) regardless of whether they received prophylaxis.
Trust your instincts. If something feels wrong, reach out to your pediatrician. Worrying about your baby means you care — that is a good thing.
Was this page helpful?
Related Medical Concerns
RSV in Babies: What to Know
RSV (respiratory syncytial virus) is a common virus that affects nearly all children by age 2. Most babies have mild cold-like symptoms, but some, especially young infants and those with underlying conditions, can develop breathing difficulties. Watch for fast breathing, flaring nostrils, or visible chest pulling - these are signs to seek medical care.
Signs of Bronchiolitis in Babies
Bronchiolitis is a common lower respiratory infection in babies under 2 years, most often caused by RSV. It typically starts like a cold with runny nose and cough, then progresses to wheezing and breathing difficulty over 2-3 days. Most cases are mild and resolve at home within 1-2 weeks, but young infants (under 3 months) and babies born prematurely are at higher risk for severe illness requiring hospitalization.
Childhood Immunization Schedule: 2026 Updates
The childhood immunization schedule is reviewed and updated annually by the CDC's Advisory Committee on Immunization Practices (ACIP), the AAP, and the American Academy of Family Physicians. The schedule may include changes to timing, new vaccine recommendations, or updates to catch-up schedules. Always consult your pediatrician for the most current recommendations, as the schedule is designed to provide the earliest possible protection during the most vulnerable periods.
My Baby's Head Shape Looks Abnormal
Many babies develop temporary head shape irregularities that are completely normal. A cone-shaped head from vaginal delivery reshapes within days. Mild positional flattening (plagiocephaly) from sleeping on the back is very common and usually improves with repositioning and tummy time. However, head shape changes involving ridges, a persistently bulging fontanelle, or rapid head growth changes should be evaluated to rule out craniosynostosis.
Achondroplasia (Dwarfism) in Babies
Achondroplasia is the most common form of short-limbed dwarfism, affecting about 1 in 15,000 to 40,000 births. It is caused by a mutation in the FGFR3 gene and is usually apparent at birth with characteristic features including short limbs, a larger head, and a prominent forehead. Intelligence is normal. With monitoring for specific complications and supportive care, children with achondroplasia lead full, active, and independent lives.
Adenoid Hypertrophy and Breathing
Adenoids are lymphoid tissue located behind the nose that help fight infection in young children. When adenoids become enlarged (adenoid hypertrophy), they can block the nasal airway, causing chronic mouth breathing, snoring, nasal speech, and sleep-disordered breathing. Enlarged adenoids are most common between ages 2-7 and are a leading cause of obstructive sleep apnea in young children. Treatment ranges from watchful waiting and nasal steroids to surgical removal (adenoidectomy) if breathing or sleep is significantly affected.